Steward Partners Investment Advisory LLC Buys 18,800 Shares of Apellis Pharmaceuticals, Inc. $APLS

by · The Cerbat Gem

Steward Partners Investment Advisory LLC raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 15.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 140,975 shares of the company’s stock after buying an additional 18,800 shares during the period. Steward Partners Investment Advisory LLC owned about 0.11% of Apellis Pharmaceuticals worth $2,440,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its position in Apellis Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 10,130,356 shares of the company’s stock valued at $221,551,000 after acquiring an additional 84,331 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Apellis Pharmaceuticals by 119.6% during the 1st quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company’s stock valued at $89,173,000 after purchasing an additional 2,220,977 shares during the period. Jennison Associates LLC increased its position in shares of Apellis Pharmaceuticals by 7.4% during the 2nd quarter. Jennison Associates LLC now owns 2,661,823 shares of the company’s stock valued at $46,076,000 after purchasing an additional 184,292 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Apellis Pharmaceuticals by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,995,271 shares of the company’s stock worth $34,545,000 after purchasing an additional 45,225 shares during the period. Finally, Canada Pension Plan Investment Board boosted its holdings in shares of Apellis Pharmaceuticals by 2,879.3% in the first quarter. Canada Pension Plan Investment Board now owns 1,048,700 shares of the company’s stock worth $22,935,000 after buying an additional 1,013,500 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Stock Down 1.1%

Shares of APLS stock opened at $21.36 on Friday. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $35.72. The company’s fifty day moving average price is $23.02 and its 200-day moving average price is $21.94. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of 68.91 and a beta of 0.70.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. During the same quarter in the prior year, the business posted ($0.46) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 133.0% compared to the same quarter last year. Sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

APLS has been the subject of several recent research reports. HC Wainwright cut their target price on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Mizuho cut their price objective on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Wall Street Zen upgraded Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Robert W. Baird raised their target price on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Wells Fargo & Company started coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 15th. They set an “overweight” rating and a $32.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $33.06.

Read Our Latest Report on APLS

Insider Buying and Selling

In related news, General Counsel David O. Watson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $20.06, for a total value of $100,300.00. Following the transaction, the general counsel directly owned 108,730 shares of the company’s stock, valued at approximately $2,181,123.80. The trade was a 4.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00. Following the sale, the chief financial officer directly owned 110,936 shares of the company’s stock, valued at approximately $3,109,536.08. This trade represents a 8.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 87,921 shares of company stock valued at $2,099,423. Corporate insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

(Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Read More